Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?

Objective The aim of the study was to investigate the
effect of chemotherapy treatment with ABVD on brain
glucose metabolism in patients with Hodgkin's
disease (HD).
Methods A total of 49 patients (23 men, 26 women; mean
age 32±9 years) diagnosed with HD were included in the
study. All of them underwent a baseline (PET0) and an
interim (PET2) 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG)
PET/computed tomography (CT) brain scan. All patients
were treated after PET0 with two cycles of ABVD consisting
of doxorubicin (adriamycin), bleomycin, vinblastine, and
dacarbazine for 2 months. Thirty-five patients were
evaluated further 15±6 days after four additional cycles
(PET6). Differences in brain 18F-FDG uptake were
analyzed by statistical parametric mapping (SPM2).
Results Compared with PET0, PET2 showed a
significantly higher metabolic activity in the right angular
gyrus (Brodmann area 39) and a significant metabolic
reduction in Brodmann areas 10, 11, and 32 bilaterally.
All these changes disappeared at PET6.
Conclusion Our results support the conclusion of a very
limited impact of ABVD chemotherapy on brain metabolism
in patients with HD.

Publication type: 
Author or Creator: 
Chiaravalloti, Agostino
Pagani, Marco
Di Pietro, Barbara
Danieli, Roberta
Tavolozza, Mario
Travascio, Laura
Caracciolo, Cristiana Ragano
Simonetti, Giovanni
Cantonetti, Maria
Schillaci, Orazio
Chapman and Hall [for] the British Nuclear Medicine Society,, London , Regno Unito
Nuclear medicine communications 34 (2013): 57–63. doi:10.1097/MNM.0b013e32835aa7de
info:cnr-pdr/source/autori:Chiaravalloti, Agostino; Pagani, Marco; Di Pietro, Barbara; Danieli, Roberta; Tavolozza, Mario; Travascio, Laura; Caracciolo, Cristiana Ragano; Simonetti, Giovanni; Cantonetti, Maria; Schillaci, Orazio/titolo:Is cerebral glucose
Resource Identifier:
ISTC Author: 
Marco Pagani's picture
Real name: